Pain Management Documentation Guide 2026
Master chronic pain documentation with comprehensive templates for opioid prescribing, controlled substance compliance, pain assessment tools, interventional procedures, and multimodal treatment tracking.
Includes PDMP requirements, DEA guidelines, risk assessment frameworks, and complete note templates.

Chronic Pain in America
Source: CDC National Health Interview Survey, DEA Guidelines 2024
Table of Contents
Pain Assessment Tools
NRS, VAS, FACES, McGill, BPI, FLACC
Initial Pain Evaluation
Comprehensive intake documentation
Opioid Prescribing
Risk assessment, consent, agreements
Chronic Pain Follow-up
Complete SOAP note structure
Controlled Substance Requirements
PDMP, DEA, state regulations
Interventional Procedures
ESI, facet blocks, SCS, trigger points
Urine Drug Screening
When to order, interpretation, documentation
Red Flags & Aberrant Behavior
Identifying and documenting misuse
Tapering Documentation
Patient-driven, provider-led, involuntary
Common Mistakes
Documentation errors to avoid
Complete Templates
Copy-paste ready documentation
FAQs
Common pain documentation questions
Pain Assessment Tools
Standardized tools for measuring and documenting pain severity and characteristics
Numeric Rating Scale (NRS)
0-10 scale where 0 = no pain and 10 = worst imaginable pain
Best Used For:
Most common for acute and chronic pain assessment
Advantages:
- โQuick
- โSimple
- โWidely understood
- โEasy to track over time
Limitations:
- โSubjective
- โCultural variations
- โDifficult for some patients
Documentation Example:
"Patient rates current pain as 7/10 (NRS), down from 9/10 at last visit"
Visual Analog Scale (VAS)
10cm line where patient marks pain intensity from no pain to worst pain
Best Used For:
Research settings and when precise measurement needed
Advantages:
- โContinuous data
- โSensitive to changes
- โNo numbers needed
Limitations:
- โRequires visual ability
- โDifficult to use verbally
- โHarder to administer
Documentation Example:
"VAS score 6.8/10 measured with ruler from left anchor point"
Wong-Baker FACES Pain Rating Scale
Six faces showing increasing pain levels (0-10)
Best Used For:
Children, cognitively impaired, language barriers
Advantages:
- โVisual
- โCross-cultural
- โEasy for children
- โNo language needed
Limitations:
- โLess precise
- โMay reflect mood not pain
- โLimited gradations
Documentation Example:
"Patient points to face #4 (hurts whole lot) on FACES scale"
McGill Pain Questionnaire (MPQ)
Comprehensive questionnaire with sensory, affective, and evaluative descriptors
Best Used For:
Complex pain syndromes, detailed pain characterization
Advantages:
- โDetailed pain quality
- โMultidimensional
- โDifferentiates pain types
Limitations:
- โTime-consuming
- โRequires literacy
- โNot for quick assessment
Documentation Example:
"McGill Pain Questionnaire shows primarily shooting, burning neuropathic descriptors with PRI score of 28"
Brief Pain Inventory (BPI)
Assesses pain severity and interference with daily activities
Best Used For:
Cancer pain, chronic pain impact assessment
Advantages:
- โMeasures function
- โValidated tool
- โShows impact on life
Limitations:
- โLonger to complete
- โMay need assistance
Documentation Example:
"BPI shows pain severity average 6/10 with moderate interference in mood (5/10) and sleep (7/10)"
FLACC Scale (Behavioral)
Face, Legs, Activity, Cry, Consolability - observational scale (0-10)
Best Used For:
Non-verbal patients, infants, severe dementia
Advantages:
- โObjective
- โNo patient report needed
- โGood for non-verbal
Limitations:
- โObserver dependent
- โMay miss internal pain
- โTraining required
Documentation Example:
"FLACC score 6/10: facial grimacing (2), tense legs (2), restless activity (1), moaning (1), difficult to console (0)"
Initial Pain Evaluation Documentation
Essential elements for comprehensive pain management intake documentation
Pain Characteristics
Required- Location(s) - primary and radiating
- Onset and duration (acute vs chronic)
- Quality (sharp, dull, burning, aching, stabbing, shooting)
- Severity (0-10 scale at rest and with activity)
- Timing (constant, intermittent, breakthrough)
- Aggravating factors
- Alleviating factors
- Previous treatments tried and outcomes
Pain History
Required- When pain started (specific date if possible)
- How pain started (injury, surgery, spontaneous)
- Progression over time (stable, worsening, improving)
- Prior pain management approaches (medications, PT, injections, surgery)
- Response to previous treatments
- Previous pain specialists seen
- History of pain-related surgeries or procedures
Functional Impact
Required- Activities of daily living affected
- Work/employment status and limitations
- Sleep disturbance (onset, maintenance, quality)
- Mood impact (depression, anxiety screening)
- Social and recreational limitations
- Exercise/physical activity tolerance
- Quality of life impact
Medical History
Required- Relevant diagnoses (spine disease, arthritis, neuropathy, cancer)
- Surgical history related to pain
- Other medical conditions (especially cardiac, renal, hepatic)
- Mental health history (depression, anxiety, PTSD, substance use)
- Prior substance use disorder history
- Family history of chronic pain or substance use disorder
Medication History
Required- Current pain medications (names, doses, frequency, duration)
- Current non-pain medications
- Previous pain medications tried (including opioids)
- Medication allergies and adverse reactions
- Over-the-counter medications and supplements
- Medication effectiveness and side effects
- PDMP review documented
Opioid Prescribing Documentation Requirements
What you must document before and during opioid therapy according to CDC guidelines and state law
Risk Assessment
Before initiating opioidsMust Document:
- Opioid Risk Tool (ORT) or SOAPP-R completed and scored
- Personal or family history of substance use disorder
- Mental health conditions (depression, anxiety, PTSD)
- Previous opioid use and response
- Risk factors: age <25, history of sexual abuse, legal issues
- Protective factors: stable support system, employment, no SUD history
- Overall risk level: Low, Moderate, or High
Example Documentation:
ORT score: 4 (moderate risk). Factors: history of alcohol use disorder in remission x5 years, current anxiety disorder well-controlled on SSRI. No personal opioid misuse history. Stable employment, married with supportive family.
Informed Consent
Before first opioid prescriptionMust Document:
- Risks discussed: addiction, overdose, respiratory depression, constipation, tolerance
- Benefits discussed: pain reduction, improved function
- Alternatives discussed: non-opioid medications, PT, injections, behavioral therapy
- Safe storage discussed
- Naloxone prescribed and education provided
- Patient questions answered
- Written informed consent signed and in chart
Example Documentation:
Opioid informed consent discussion completed. Discussed risks including addiction (8-12% lifetime risk), overdose risk (especially with concurrent benzodiazepines), respiratory depression, constipation, hormonal effects. Benefits: moderate pain relief, improved function. Alternatives: NSAIDs, gabapentin, PT, lumbar ESI discussed. Patient chooses trial of opioid. Naloxone coprescribed with demonstration of use. Written consent signed.
Treatment Agreement
Before initiating chronic opioid therapyMust Document:
- Opioid treatment agreement signed
- Agreement includes: single prescriber/pharmacy, UDT requirements, pill counts
- Consequences of agreement violations discussed
- Lost/stolen prescription policy reviewed
- Early refill policy stated
- PDMP monitoring consent
- Patient verbalized understanding
Example Documentation:
Opioid treatment agreement reviewed and signed. Patient agrees to: obtain opioids from single provider/pharmacy, submit to random UDT, allow PDMP checks, secure storage, no early refills except documented exceptions. Understands violations may result in taper/discontinuation. Patient verbalized understanding and agreement.
PDMP Check
Before initial prescription and periodically (state-specific)Must Document:
- PDMP checked on [date]
- Results: consistent/inconsistent with patient report
- Prescribers identified
- Controlled substances identified with dates
- Any concerning patterns noted
- Discussion with patient if discrepancies
- Action taken based on findings
Example Documentation:
PDMP reviewed 1/15/2026: Shows oxycodone 10mg from this provider only, filled monthly as prescribed. No other controlled substances. No early fills. No multiple prescribers. Consistent with patient report. Will recheck in 3 months per protocol.
CDC 2022 Opioid Guideline Updates
The 2022 CDC guidelines replace the 2016 version with less rigid thresholds and more individualized care:
- โข Removed arbitrary dose thresholds (previously "avoid >90 MME/day")
- โข Emphasizes individualized care over population-level limits
- โข Discourages rapid/forced tapers (can cause harm)
- โข Still recommends starting low dose, caution at โฅ50 MME/day
- โข Document rationale if exceeding typical dosing ranges
Chronic Pain Follow-Up Note Structure
Complete SOAP note template for chronic pain management visits
Chief Complaint & Interval History
Include These Elements:
- โขReason for visit (routine follow-up, pain flare, medication adjustment)
- โขPain level today vs last visit (0-10 scale)
- โขPain pattern since last visit (stable, improved, worsened)
- โขCurrent pain locations and characteristics
- โขMedication effectiveness and side effects
- โขCompliance with treatment plan
- โขNew symptoms or concerns
Example:
CC: "Routine chronic low back pain follow-up" Interval History: Patient presents for 3-month follow-up of chronic lumbar radiculopathy. Since last visit: - Pain level: 5/10 today (range 4-7/10 over past 3 months), previously 6-8/10 - Location: Lower back L4-S1 with radiation to right posterior leg to calf - Quality: Aching in back, shooting/burning in leg - Pain is 30% improved since starting gabapentin and completing PT course - Reports improved function: can walk 30 minutes (was 10 minutes), sleeping better - Medication compliance: Taking oxycodone 10mg TID as prescribed, gabapentin 600mg TID - Side effects: Mild constipation managed with Miralax, no sedation or cognitive issues - No requests for early refills, no lost/stolen medications - Completed 12-session PT course with home exercise program compliance
Functional Assessment
Include These Elements:
- โขActivities of daily living (bathing, dressing, cooking)
- โขInstrumental ADLs (work, shopping, housework)
- โขSleep quality and quantity
- โขExercise/physical activity level
- โขSocial engagement
- โขMood and psychological wellbeing
- โขComparison to previous function
Example:
Functional Status: - ADLs: Independent in all activities, can shower without sitting (new improvement) - Work: Returned to part-time desk work 20 hrs/week (up from 10 hrs/week), tolerating well - Sleep: 7 hours nightly, wakes 1-2x vs 4-5x previously - Exercise: Walking 30 min daily, home PT exercises 5 days/week - Social: Attended daughter's soccer game last weekend (couldn't do before) - Mood: PHQ-9 score 6 (mild, down from 12 moderate at baseline) - Overall function: 60% of pre-injury baseline (was 30% at initial visit)
Physical Examination
Include These Elements:
- โขGeneral appearance and mood
- โขFocused exam of pain area
- โขNeurological exam if neuropathic pain
- โขGait and mobility
- โขFunctional movements
- โขChanges from previous exam
Example:
Physical Exam: General: Alert, pleasant, cooperative, no acute distress Back: No deformity, tenderness L4-S1 paraspinal muscles, no midline tenderness Neuro: - Strength: 5/5 bilateral lower extremities (including dorsiflexion, plantarflexion) - Sensation: Diminished light touch right L5 distribution (unchanged) - Reflexes: 2+ symmetric knee, 1+ right ankle (previously absent) - Straight leg raise: Negative bilaterally (previously positive right 45 degrees) Gait: Antalgic gait improved, able to heel/toe walk Functional: Can stand from sitting without armrests, forward flexion limited to 45 degrees
Medication Review & PDMP
Include These Elements:
- โขAll current pain medications with doses
- โขOpioid morphine milligram equivalent (MME) if applicable
- โขPDMP check results
- โขPill count results if performed
- โขUrine drug screen results if performed
- โขMedication effectiveness rating
- โขSide effects present
Example:
Medications: 1. Oxycodone 10mg PO TID (90 tablets/month) = 45 MME/day 2. Gabapentin 600mg PO TID 3. Acetaminophen 500mg PO PRN 4. Docusate 100mg PO BID PDMP checked today: Shows only oxycodone from this practice, filled monthly on schedule. Last fill 12/18/25 for 90 tablets. No other controlled substances. No other prescribers. No early fills. UDT (performed 1/10/26): Positive for oxycodone and gabapentin (prescribed), negative for other opioids, benzodiazepines, THC, cocaine, amphetamines. Creatinine normal. Consistent with prescribed regimen. Effectiveness: Patient rates medication regimen as 7/10 effectiveness for pain control Side effects: Mild constipation (managed), no sedation, no cognitive impairment noted
Assessment
Include These Elements:
- โขPrimary pain diagnosis with ICD-10
- โขPain type (nociceptive, neuropathic, mixed, nociplastic)
- โขContributing factors
- โขComorbid conditions
- โขTreatment response
- โขRisk assessment update
- โขFunctional goals progress
Example:
Assessment: 1. Chronic low back pain with right lumbar radiculopathy, L4-L5 disc herniation (M54.16, M51.16) - Mixed nociceptive and neuropathic pain - MRI 6/2025: L4-L5 disc herniation with nerve root compression - Improved 30% since multimodal treatment initiation - Functional improvement: returned to part-time work, improved mobility 2. Treatment response: GOOD - Pain reduced from 7/10 to 5/10 average - Function improved from 30% to 60% of baseline - Opioid dose stable at 45 MME/day (below CDC guideline threshold) - No aberrant behaviors, UDT and PDMP compliant 3. Opioid risk: LOW-MODERATE (unchanged) - No requests for early refills - PDMP shows single provider/pharmacy - UDT consistent with prescribed medications - Good functional improvement demonstrates appropriate use
Plan
Include These Elements:
- โขContinue, adjust, or taper medications
- โขNon-pharmacologic treatments recommended
- โขInterventional procedures planned
- โขReferrals needed
- โขMonitoring plan (UDT, PDMP, pill counts)
- โขFunctional goals
- โขFollow-up interval
- โขPatient education provided
Example:
Plan: 1. Medications: - Continue oxycodone 10mg TID (stable dose, good response, 45 MME/day) - Continue gabapentin 600mg TID (effective for neuropathic component) - Continue bowel regimen 2. Interventional: Refer to pain specialist for consideration of right L4-L5 transforaminal ESI given persistent radicular symptoms 3. Non-pharmacologic: - Continue home PT exercise program - Initiate CBT for pain management (referral placed) - Encourage continued walking program, increase to 45 min daily 4. Monitoring: - Next UDT in 3 months (due April 2026) - PDMP recheck at next visit - Random pill count may be performed 5. Goals for next 3 months: - Increase work to 30 hours/week - Reduce pain to 4/10 average - Wean opioid if ESI effective 6. Follow-up: 3 months (April 2026) or sooner if pain worsens - Call if pain increases >8/10, new symptoms, or medication concerns 7. Education: Reviewed safe storage, no driving within 4 hours of opioid dose, naloxone use reviewed Prescriptions: - Oxycodone 10mg #90, 1 tablet TID, 0 refills (3-month supply) - Gabapentin 600mg #270, 1 tablet TID, 3 refills
Controlled Substance Documentation Requirements
Federal DEA and state PDMP requirements for prescribing controlled substances
PDMP Requirements
State Prescription Drug Monitoring Programs track controlled substance prescriptions
Coverage:
All 50 states + DC have PDMP programs
Mandatory Checking:
- โBefore initial opioid prescription (all states)
- โPeriodically during chronic therapy (varies: every 3 months to annually)
- โWhen suspicious activity detected
- โSome states: delegate authority to staff to check
Documentation Template:
"PDMP checked [date]. Results: [consistent/inconsistent with patient report]. Shows [medications, prescribers, pharmacies]. Action taken: [continue/discuss discrepancy/refer to addiction medicine]"
DEA Registration
DEA registration required to prescribe controlled substances
DEA Schedules:
- โข Schedule II: Oxycodone, morphine, fentanyl, hydromorphone (no refills)
- โข Schedule III: Hydrocodone/acetaminophen, buprenorphine (up to 5 refills in 6 months)
- โข Schedule IV: Tramadol, benzodiazepines (up to 5 refills in 6 months)
- โข Schedule V: Cough preps with codeine (up to 5 refills in 6 months)
Prescribing Rules:
- โขElectronic prescribing required in most states (EPCS)
- โขHandwritten Schedule II Rx requires tamper-proof paper in some states
- โขMust include: DEA number, patient address, drug name/strength/quantity, directions, prescriber signature
Documentation Standards
What must be documented for controlled substance prescribing
Federal Requirements:
- โขMedical indication for controlled substance
- โขInformed consent for opioid therapy
- โขRisk-benefit assessment
- โขTreatment goals (pain AND function)
- โขPeriodic review of therapy effectiveness
State-Specific Additional Requirements:
- โ Many states: mandatory PDMP check documentation
- โ Some states: mandatory co-prescription of naloxone
- โ Some states: consultation requirements for high-dose opioids (>90-120 MME)
- โ Mandatory continuing education on pain/addiction (hours vary by state)
Interventional Procedure Documentation
How to document injections, nerve blocks, RFA, and implantable devices
Epidural Steroid Injections (ESI)
Indications:
Radicular pain from disc herniation, spinal stenosis, radiculopathy
Required Documentation:
- Diagnosis with imaging correlation (MRI findings)
- Failed conservative treatment (PT, medications) with specific duration
- Examination findings supporting radiculopathy
- Level(s) to be injected based on clinical/imaging correlation
- Patient consent including risks (infection, bleeding, nerve injury, paralysis rare)
- Procedure note: approach, level, medications/doses, fluoroscopic guidance, complications
- Post-procedure: pain relief percentage, duration, functional improvement
Follow-Up Documentation Example:
Patient reports 60% pain relief after right L5-S1 transforaminal ESI performed 1/5/26. Duration of relief: 3 months. Functional improvement: returned to work. Plan: repeat if benefit wanes, consider RFA if 3+ injections provide temporary relief.
Facet Joint Injections & Medial Branch Blocks
Indications:
Axial low back or neck pain from facet arthropathy
Required Documentation:
- Clinical criteria: axial pain worse with extension, tenderness over facets
- Imaging: facet arthropathy on X-ray, CT, or MRI
- Diagnostic blocks: document % pain relief and duration
- If >50% relief from 2 separate medial branch blocks, candidate for RFA
- RFA documentation: levels treated, technique, complications, expected results
Follow-Up Documentation Example:
Phase 1 diagnostic medial branch blocks L3-L5 performed 12/1/25 with 80% pain relief x4 hours. Phase 2 blocks 12/20/25 with 75% relief x5 hours. Criteria met for radiofrequency ablation. RFA L3-L5 performed 1/15/26. Expect peak relief at 4-6 weeks.
Spinal Cord Stimulator (SCS)
Indications:
Failed back surgery syndrome, complex regional pain syndrome, neuropathic pain
Phases:
Required Documentation:
- Diagnosis and pain duration (typically >6 months)
- Failed conservative treatment: medications, PT, injections
- Psychological evaluation clearance (required)
- Trial results: % pain relief, functional improvement, opioid reduction
- Permanent implant: programming parameters, pain relief, function, opioid reduction goals
- Follow-up: battery checks, reprogramming, pain/function tracking
Follow-Up Documentation Example:
SCS trial 12/1-12/7/25: 70% pain relief, walked 1 mile (baseline 0.25 miles), reduced oxycodone from 60mg to 40mg daily. Trial deemed successful. Permanent implant 12/20/25. Current settings: Program 2, amplitude 4.0mA. Pain 3/10 (was 8/10). Opioid reduced to 30mg daily. Functional goal: return to part-time work in 3 months.
Trigger Point Injections
Indications:
Myofascial pain syndrome, muscle spasm, fibromyalgia
Required Documentation:
- Palpable taut bands or trigger points identified
- Locations of injections (specific muscles)
- Medications and doses used
- Number of injection sites
- Immediate pain relief response
- Expected duration of relief
Follow-Up Documentation Example:
Trigger point injections performed 1/10/26: bilateral trapezius, levator scapulae (6 sites total) with 1% lidocaine 1mL per site. Immediate 50% pain relief. Patient reports relief lasted 2 weeks. Repeat injections offered monthly x3 months, then reassess. Recommended concurrent PT for posture and strengthening.
Urine Drug Screening Documentation
When to order, how to interpret, and what to document for UDT in pain management
When to Order UDT
- Before initiating chronic opioid therapy (baseline)
- Randomly at least annually (some recommend every 3-6 months)
- When aberrant behavior suspected
- When PDMP shows concerning patterns
- When patient reports lost/stolen medications
Best Practice: Random schedule prevents gaming, but have consistent practice policy
Types of UDT
Testing Methods:
Insurance Coverage: Most insurance covers UDT for pain management, but check frequency limits and authorization needs
Expected Results
Result Interpretation:
- โข Positive for prescribed opioids - expected
- โข Negative for prescribed opioids - concerning (not taking medication, diversion possible)
- โข Positive for non-prescribed controlled substances - concerning (illicit use or other prescriber)
- โข Unexpected medications - discuss with patient before assuming non-compliance
Documentation: Document results, interpretation, patient discussion, and action taken
Documentation Examples
Expected Result Documentation:
UDT 1/15/26: Positive for oxycodone (prescribed), negative for other opioids, benzodiazepines, THC, cocaine, amphetamines. Creatinine 150 mg/dL (normal, not dilute). Consistent with prescribed medication regimen. Will continue current treatment plan.
Unexpected Positive Documentation:
UDT 1/15/26: Positive for oxycodone (prescribed) AND hydrocodone (not prescribed). PDMP check shows hydrocodone prescription from orthopedic surgeon 1/5/26 for acute dental pain. Patient stated they forgot to mention dental visit. Educated on importance of disclosing all prescriptions. Will continue current plan, recheck PDMP quarterly.
Unexpected Negative Documentation:
UDT 1/15/26: Negative for oxycodone despite prescription for 10mg TID. Patient states they are taking medication as prescribed. Possible explanations discussed: individual metabolism, last dose timing. Repeated UDT observed collection scheduled for next week. Discussed importance of medication compliance and truthfulness. Continued prescription with shorter follow-up interval.
Red Flags & Aberrant Behavior Documentation
Identifying and documenting concerning behaviors in pain management
Red Flags for Opioid Misuse
Behaviors to Document:
How to Document: Document specific behavior, date/time, patient's explanation, PDMP findings, UDT results, and action taken
Yellow Flags - Concerning but May Have Explanation
Behaviors to Document:
How to Document: Document behavior, obtain explanation, provide education, increase monitoring frequency, document patient response
Red Flag Documentation Example:
Red flag behavior documented 1/15/26: Patient called requesting early refill of oxycodone, stating prescription was stolen from car 10 days into 30-day supply. This is the second "lost/stolen" report in 6 months (previous 8/20/25). PDMP checked: shows this practice only. UDT from 12/1/25 was negative for oxycodone. Informed patient no early refill will be provided per practice policy. Discussed discrepancy between "taking as prescribed" and negative UDT. Patient became verbally aggressive, demanded to speak to office manager. Notified patient that continued aggressive behavior will result in discharge from practice. Scheduled urgent appointment with addiction medicine for evaluation. Will not prescribe further opioids until addiction medicine assessment completed. Patient refused addiction medicine referral. Initiated opioid taper plan per practice protocol.
Yellow Flag Documentation Example:
Yellow flag noted 1/15/26: Patient requested dose increase from oxycodone 10mg TID to 15mg TID, reporting tolerance developing after 18 months at current dose. Pain increased from 5/10 to 7/10 average. UDT and PDMP compliant. No other aberrant behaviors. Discussed: tolerance is expected, dose escalation not always beneficial, ceiling effect. Reviewed multimodal options: increase gabapentin, trial duloxetine, referral for interventional procedure (ESI). Patient agreed to trial duloxetine and continue current opioid dose. Increase monitoring: follow-up in 4 weeks (instead of 12 weeks), UDT at next visit. If pain not improved, will refer to pain specialist for interventional options before considering dose increase.
Opioid Tapering Documentation
How to document patient-driven, provider-recommended, and involuntary tapers
Patient-Driven Taper
Indication: Patient requests to reduce or stop opioid therapy
Approach:
- Support patient decision
- Slow taper: reduce 5-10% of dose per week/month
- More gradual for long-term/high-dose users
- Monitor withdrawal symptoms
- Optimize non-opioid treatments
- Frequent follow-up during taper
Complete Documentation Example:
Patient-initiated opioid taper: Patient requests discontinuation of oxycodone due to side effects (constipation, cognitive fog) despite adequate pain control. Current dose 30mg daily x 2 years. Taper plan: reduce 5mg every 2 weeks (10% dose reduction). Week 1-2: 25mg daily. Week 3-4: 20mg daily. Continue until discontinued over 12 weeks. Increased gabapentin to 900mg TID. Scheduled PT consult. Follow-up every 2 weeks during taper. Educated on withdrawal symptoms (anxiety, sweating, muscle aches, insomnia) and when to slow taper. Patient verbalized understanding and agreement.
Provider-Recommended Taper
Indication: Lack of efficacy, harm exceeds benefit, improved function making opioids unnecessary
Approach:
- Shared decision-making
- Explain rationale clearly
- Collaborate on taper rate
- Address patient concerns
- Maximize non-opioid treatments
- Consider referral to addiction medicine or pain specialist
Complete Documentation Example:
Provider-recommended taper: Patient on oxycodone 60mg daily x 3 years for chronic low back pain. Despite opioid therapy, pain unchanged 8/10, no functional improvement, PHQ-9 increased from 8 to 16. Risk exceeding benefit. Discussed with patient: opioids not providing pain or functional benefit, contributing to depression, risk of harm. Collaborative taper plan developed: reduce 10mg every month over 6 months. Simultaneously increase multimodal treatment: initiate duloxetine 30mg daily (titrate to 60mg), PT referral, CBT for pain referral, consider SCS trial. Follow-up monthly during taper. Patient initially resistant, educated on lack of benefit and risks. Patient agreed to trial taper with agreement to slow/pause if intolerable. Written taper plan provided.
Involuntary Taper/Discontinuation
Indication: Aberrant behavior, diversion, violation of treatment agreement
Approach:
- Document specific violations clearly
- Ensure patient safety during discontinuation
- Cannot abruptly stop high-dose opioids (medical instability)
- Rapid taper with close monitoring or referral
- Offer addiction treatment referral
- Document patient notification
Complete Documentation Example:
Involuntary opioid discontinuation: Patient found to be obtaining oxycodone from 3 different providers per PDMP check 1/15/26 (this practice, Dr. Smith - orthopedics, Dr. Jones - urgent care). When confronted, patient admitted to "shopping" for extra pills due to running out early. This violates opioid treatment agreement signed 6/1/25 (single provider clause). Per practice policy, opioid therapy will be discontinued. Given patient on high dose (90 MME/day x 18 months), abrupt discontinuation unsafe. Rapid taper plan: Week 1-2: reduce to 60 MME. Week 3-4: reduce to 30 MME. Week 5-6: reduce to 15 MME. Week 7-8: discontinue. Provided referral to addiction medicine (phone number given, appointment scheduled). Educated on withdrawal symptoms and safety. Patient expressed anger but understands policy. Will continue non-opioid pain care (gabapentin, PT) with monthly visits during taper. If patient refuses taper visits or misses appointments, will provide 1 final 2-week prescription with addiction medicine warm handoff.
Warning: Avoid Forced Rapid Tapers
The 2022 CDC guidelines warn against forced rapid tapers which can cause severe harm:
- โข Increased suicide risk during rapid tapers
- โข Withdrawal symptoms can be severe and dangerous
- โข May drive patients to illicit opioids
- โข Taper collaboratively with patient input on rate
- โข Document that taper pace is individualized to patient tolerance
Common Pain Management Documentation Mistakes
Avoid these frequent errors that lead to compliance issues and liability
Not documenting pain AND function
Why it matters: Pain score alone doesn't justify opioids; functional improvement is key outcome
Fix: Always document functional goals and progress (ADLs, work, sleep, exercise, social engagement)
WRONG: "Pain 6/10, continue oxycodone" | RIGHT: "Pain 6/10, functional improvement: returned to work 20hrs/week (goal met), walking 30 min daily (up from 10 min), sleep improved 5hrs to 7hrs. Continue oxycodone with current benefit."
Not documenting PDMP checks
Why it matters: Required by law in most states; failure to check can lead to licensing issues
Fix: Document every PDMP check with date, findings, and clinical decision
PDMP checked 1/15/26: oxycodone from this practice only, filled monthly on schedule, no other controlled substances, no red flags. Will recheck in 3 months.
Vague pain descriptions
Why it matters: Doesn't support medical necessity or help with diagnosis
Fix: Use specific descriptors, location, radiation, quality, severity, aggravating/alleviating factors
WRONG: "Back hurts" | RIGHT: "Constant aching pain 7/10 in lower lumbar region L4-S1, radiating shooting/burning pain down right posterior leg to calf, worse with sitting >30min and forward bending, improved with standing and walking"
No documentation of alternatives tried
Why it matters: Opioids should not be first-line; documentation must show conservative treatment failure
Fix: List specific non-opioid treatments tried with durations and outcomes before opioid initiation
Conservative treatments failed: NSAIDs x6 weeks (inadequate relief, GI upset), PT x12 sessions (minimal improvement), gabapentin titrated to 2400mg/day (ineffective), lumbar ESI x2 (no relief). Due to failed conservative care and severe functional impairment, trial of opioid therapy offered.
Missing informed consent documentation
Why it matters: Required for opioid prescribing; protects provider and patient
Fix: Document risks/benefits discussion and signed consent before first opioid prescription
Opioid informed consent completed 1/15/26. Discussed risks (addiction 8-12%, overdose, respiratory depression, constipation, hormonal effects, tolerance), benefits (moderate pain relief, improved function), alternatives (non-opioid meds, injections, surgery). Patient chose trial of opioid. Naloxone prescribed. Written consent signed and scanned to chart.
No MME calculation documented
Why it matters: CDC recommends caution at โฅ50 MME/day and avoiding โฅ90 MME/day
Fix: Calculate and document total daily MME, especially if multiple opioids or combination products
Total daily MME: Oxycodone 10mg TID (30mg/day x 1.5 conversion = 45 MME/day). Below CDC 50 MME caution threshold.
Complete Documentation Templates
Copy-paste ready templates for pain management documentation
Initial Pain Evaluation Template
PAIN MANAGEMENT INITIAL CONSULTATION PATIENT: [Name], [Age] y/o [M/F] DATE: [Date] REFERRING PROVIDER: [Name] CHIEF COMPLAINT: [Patient's description of pain problem] PAIN HISTORY: Location: [Primary site(s) and radiation pattern] Onset: [Date/circumstances of pain onset] Duration: [How long patient has had pain] Quality: [Sharp, dull, burning, aching, stabbing, shooting, throbbing, etc.] Severity: [0-10 scale] Currently: ___/10, Average: ___/10, Best: ___/10, Worst: ___/10 Timing: [Constant, intermittent, breakthrough episodes] Aggravating Factors: [What makes pain worse] Alleviating Factors: [What makes pain better] PREVIOUS TREATMENTS: Medications Tried: 1. [Medication] - [Dose] - [Duration] - [Outcome/reason for discontinuation] 2. [...] Physical Therapy: [Y/N, duration, outcome] Injections: [Type, location, date, % relief, duration] Surgery: [Type, date, outcome] Alternative Therapies: [Acupuncture, chiropractic, massage, etc.] CURRENT MEDICATIONS: [List all medications with doses and frequencies] Pain Medications: [...] Other Medications: [...] Allergies: [Medication allergies and reactions] FUNCTIONAL IMPACT: Work Status: [Full-time, part-time, disabled, modified duty, unemployed] Activities of Daily Living: [Independent, needs assistance with: ___] Sleep: [Hours per night, difficulty falling/staying asleep, quality] Mood: PHQ-9 score: ___ ([None/Mild/Moderate/Moderately Severe/Severe]) Exercise: [Type, frequency, limitations] Social Impact: [Activities stopped, relationships affected] SUBSTANCE USE HISTORY: Tobacco: [Current/former/never, pack-years] Alcohol: [Drinks per week] Illicit Drugs: [Current/past use, substances, last use] History of Substance Use Disorder: [Y/N, details, treatment, remission length] PHYSICAL EXAMINATION: General: [Appearance, mood, distress level] [Focused exam of pain region - spine, joints, neuro as appropriate] [Include relevant neurological exam if neuropathic pain] IMAGING REVIEW: [Review of X-rays, MRI, CT with findings relevant to pain] ASSESSMENT: 1. [Primary pain diagnosis] ([ICD-10 code]) - [Pain type: nociceptive, neuropathic, mixed, nociplastic] - [Severity: mild, moderate, severe based on pain scores and functional impact] 2. [Secondary diagnoses] 3. Functional Status: [Baseline function level] OPIOID RISK ASSESSMENT (if considering opioid therapy): - Opioid Risk Tool Score: ___ ([Low <4, Moderate 4-7, High >7]) - Risk Factors: [List relevant factors] - Protective Factors: [List relevant factors] - Overall Risk Level: [LOW / MODERATE / HIGH] PDMP Review: [Date checked, findings] TREATMENT PLAN: Goals: 1. Pain reduction to ___/10 2. Functional goals: [Specific, measurable - return to work, walk X distance, sleep through night, etc.] 3. [Additional goals] Medications: 1. [Medication, dose, frequency, indication] 2. [...] [Include MME calculation if opioid prescribed] If Initiating Opioid Therapy: - Informed consent: Completed and signed [Date] - Treatment agreement: Signed [Date] - Naloxone: Prescribed, education provided - Monitoring plan: UDT at baseline and every [interval], PDMP every [interval] Non-Pharmacologic: - Physical therapy: [Plan] - Interventional procedures: [Considering ___] - Behavioral health: [CBT, pain psychology, biofeedback] - Exercise/activity modification: [Recommendations] Referrals: - [Specialists as needed] Follow-up: [Timeframe] - Sooner if: [Red flags requiring earlier follow-up] Patient Education: - [Topics discussed: safe storage, side effects, when to call, etc.] Time spent: [Total visit time], >50% counseling and coordination [Provider signature] [Date/Time]
Chronic Pain Follow-Up Template
CHRONIC PAIN FOLLOW-UP PATIENT: [Name] DATE: [Date] INTERVAL: [Time since last visit] CHIEF COMPLAINT: "[Patient quote]" INTERVAL HISTORY: Pain Level: Today ___/10, Average since last visit ___/10 (Previously ___/10) Pattern: [Improved, stable, worsened] Location: [Current pain sites] Changes: [Any new pain, resolved pain, changes in character] Medication Review: Current Pain Medications: 1. [Medication] [Dose] [Frequency] - Compliance: [Good/partial/poor] - Effectiveness: [0-10 scale or % relief] - Side effects: [List or "none reported"] [For opioids - calculate total daily MME] Total MME/day: ___ ([Below/at/above] CDC thresholds) Medication Requests: [Early refills, dose changes, etc.] Functional Assessment: - Work: [Status and any changes] - ADLs: [Independent or assistance needed] - Sleep: [Hours, quality] - Exercise: [Type, frequency, tolerance] - Social: [Activities, engagement] - Mood: PHQ-9: ___ (Previous: ___) - Overall Function: [% of pre-injury baseline, comparison to last visit] MONITORING: PDMP Check: [Date] - Findings: [Consistent/inconsistent, prescribers, red flags] UDT Results: [Date] - [Expected medications present/absent, unexpected findings] Interpretation: [Consistent/inconsistent with prescribed regimen] Patient discussion: [If abnormal] Pill Count: [If performed - date, result] Aberrant Behaviors: [None / Describe any concerning behaviors] PHYSICAL EXAMINATION: General: [Appearance, affect, distress level] [Focused exam of pain area with comparison to previous exam] Functional: [Gait, ROM, ability to perform activities] ASSESSMENT: 1. [Primary pain diagnosis] ([ICD-10]) - [Improved/Stable/Worsened] - Pain: [Change from baseline] - Function: [Change from baseline] - Treatment response: [GOOD/PARTIAL/POOR] 2. Chronic opioid therapy (if applicable): - Current dose: [MME/day] - Benefit vs. risk: [Benefit exceeds risk / Risk exceeds benefit] - Monitoring compliance: [Compliant/non-compliant with UDT, PDMP, pill counts] - Opioid risk level: [LOW/MODERATE/HIGH] 3. Progress toward goals: - [Goal 1]: [Met/progressing/not met] - [Goal 2]: [Met/progressing/not met] PLAN: Medications: - [Continue/Adjust/Taper/Discontinue] [medication] - [Rationale for changes] Non-Pharmacologic: - [PT, behavioral health, exercise, other modalities] Interventional Procedures: - [Planned procedures, follow-up on previous procedures] Monitoring: - Next UDT: [Date] - Next PDMP check: [Date] - Next visit: [Interval] Goals for next visit: 1. [Specific functional goal] 2. [Specific pain goal] 3. [Other goals] Patient Education: - [Topics reviewed: medication safety, storage, side effects, goals, etc.] Red Flags Reviewed: - Call or go to ER if: [Specific warning signs] Prescriptions: - [Medication] #[Quantity], [Directions], [Refills] Follow-up: [Timeframe] or sooner if [specific circumstances] [Provider signature] [Date/Time]
Template Usage Tips
- โข Always customize templates for each patient's specific situation
- โข Replace all bracketed [placeholders] with actual patient data
- โข Delete sections that don't apply rather than leaving blank
- โข Add additional detail where clinically relevant
- โข These templates ensure you don't miss required elements
Automate Pain Management Documentation with AI
PatientNotes AI generates comprehensive pain management notes including functional assessments, MME calculations, PDMP documentation prompts, and all required opioid therapy elements.
Frequently Asked Questions
Common pain management documentation questions answered.
What documentation is required when prescribing opioids for chronic pain?
Required documentation includes: informed consent discussion with risks/benefits, treatment agreement signed, baseline risk assessment (ORT or SOAPP-R), PDMP check documented, treatment goals for pain AND function, periodic monitoring plan (UDT frequency, PDMP rechecks), and calculation of total daily morphine milligram equivalent (MME). Each follow-up visit should document pain levels, functional status, medication effectiveness, side effects, PDMP results, UDT results if performed, and progress toward treatment goals.
How often do I need to check the PDMP?
PDMP checking requirements vary by state. Most states require checking before the initial opioid prescription and periodically during chronic therapy (every 3 months is common, though some states require it at every visit and others annually). Always check the PDMP when aberrant behavior is suspected, when a patient reports lost/stolen medications, or when the patient requests early refills. Document every PDMP check with the date and findings in the medical record.
What pain assessment tools should I use?
The Numeric Rating Scale (0-10) is the most common and appropriate for most patients. Use the Wong-Baker FACES scale for children or patients with cognitive impairment. The Brief Pain Inventory (BPI) is excellent for assessing both pain severity AND functional interference. For complex pain, consider the McGill Pain Questionnaire. Use the FLACC scale for non-verbal patients. Whatever tool you choose, use it consistently to track changes over time.
How do I document functional improvement or lack thereof?
Document specific, measurable functional outcomes: work status (hours per week, duties performed), activities of daily living (bathing, dressing, cooking without assistance), sleep (hours per night, quality), exercise tolerance (can walk X minutes/miles), social engagement (attending events, hobbies resumed). Compare to baseline and previous visits. Functional improvement is more important than pain scores alone when assessing opioid therapy effectiveness. If function is not improving despite opioid therapy, document this as evidence that risk may exceed benefit.
What should I document for interventional procedures like epidural steroid injections?
Pre-procedure: document diagnosis with imaging correlation (e.g., L5-S1 disc herniation on MRI), failed conservative treatments with specific durations, exam findings supporting the diagnosis, patient consent including risks discussed. Procedure note: approach used, level(s) injected, medications and doses, fluoroscopic guidance used, any complications. Post-procedure: percentage pain relief, duration of relief, functional improvements achieved, and plan for future injections or alternative treatments based on response.
How do I document a patient with aberrant behavior or suspected opioid misuse?
Document specific objective behaviors (not judgments): "Patient called requesting early refill stating pills were lost, third time in 12 months" rather than "patient is drug-seeking." Include: date/time of behavior, patient's exact words/explanation, PDMP findings showing the behavior, UDT results if relevant, previous similar behaviors, and specific action taken (e.g., refused early refill per policy, increased monitoring, referred to addiction medicine, initiated taper). Avoid inflammatory language while being clear about facts and clinical concerns.
What is the correct way to calculate morphine milligram equivalents (MME)?
Calculate total daily opioid dose in milligrams, then multiply by the opioid conversion factor: Morphine (1.0), Oxycodone (1.5), Hydrocodone (1.0), Hydromorphone (4.0), Fentanyl patch mcg/hr (2.4), Methadone (varies - complex conversion). Example: Oxycodone 10mg three times daily = 30mg/day ร 1.5 = 45 MME/day. Document this calculation, especially if approaching CDC guideline thresholds (caution at โฅ50 MME/day, avoid or justify โฅ90 MME/day).
Can AI help with pain management documentation?
Yes, AI documentation tools like PatientNotes can help ensure comprehensive pain management notes by prompting for required elements (pain scores, functional assessment, PDMP documentation, MME calculation), tracking changes over time, and generating templates that meet regulatory requirements. AI can help ensure you document both pain AND function, include all required elements for opioid prescribing, and maintain consistent follow-up documentation. However, providers must still perform clinical assessments, PDMP checks, and clinical decision-making.
Related Resources
Ready to Streamline Pain Management Documentation?
Join pain management specialists using PatientNotes to automate compliant chronic pain documentation with built-in PDMP prompts, MME calculations, and functional assessments.
Try PatientNotes Free - 7 Day Trial